MXene-mediated fluorescent recombinase polymerase amplification for rapid and sensitive DNA methylation biosensing.

IF 6.1 1区化学 Q1 CHEMISTRY, ANALYTICAL Talanta Pub Date : 2025-05-15 Epub Date: 2025-02-03 DOI:10.1016/j.talanta.2025.127685

Bingshan Guo, Jiaoying Peng, Yongzhi Wang, Ying Chen, Ran Li, Xuemei Xu, Yongchao Yao, Wenchuang Walter Hu

引用次数: 0

Abstract

DNA methylation serves as a promising biomarker for early cancer detection, with its assessment providing crucial insights for prognosis and diagnosis. Herein, we present a novel MXene-mediated fluorescent recombinase polymerase amplification (RPA) strategy that achieves rapid and sensitive non-small cell lung cancer (NSCLC)-associated methylated DNA detection. Remarkably, MXene can effectively quench the fluorescence of fluorescein amidate (FAM) labeled primer, with fluorescence recovery occurring as primers extend to double-stranded DNA and are released during the RPA process. This method exhibits exceptional sensitivity and selectivity, enabling the detection of methylated DNA at concentrations as low as 10 fM, with assay completion achieved in less than 1 h. Its ability to precisely evaluate gene-specific methylation showcases its potential to advance methylation as a disease biomarker, particularly in NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

mxene介导的荧光重组酶聚合酶扩增用于快速和敏感的DNA甲基化生物传感。

DNA甲基化是一种很有前景的早期癌症检测生物标志物，其评估为预后和诊断提供了重要的见解。在此，我们提出了一种新的mxene介导的荧光重组酶聚合酶扩增（RPA）策略，实现了快速和敏感的非小细胞肺癌（NSCLC）相关甲基化DNA检测。值得注意的是，MXene可以有效地猝灭荧光素酰胺（FAM）标记引物的荧光，当引物延伸到双链DNA并在RPA过程中释放时，荧光恢复。该方法具有卓越的灵敏度和选择性，能够在低至10 fM的浓度下检测甲基化DNA，在不到1小时内完成检测。其精确评估基因特异性甲基化的能力显示了其作为疾病生物标志物，特别是在非小细胞肺癌中推进甲基化的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Talanta 化学-分析化学

CiteScore

12.30

自引率

4.90%

发文量

861

审稿时长

29 days

期刊介绍： Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome. Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.